Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial

Conclusions Pasireotide therapy can provide normalization of UFC and of clinical symptoms and signs of CD during up to 5 years of follow-up. This study demonstrates the possible recuperation of normoglycemia after continued use of pasireotide and control of underlying hypercortisolemia. Longer-term monitoring for potential adverse events related to continued use of pasireotide is indicated.

http://link.springer.com/10.1007/s11102-013-0539-4

Source: Pituitary - November 6, 2014 Category: Endocrinology Source Type: research